In terms of the remote inspections, it's true that we relied more on those over the pandemic, but it wasn't the first time we had done those sorts of paper-based assessments of facilities.
First of all, the remote inspections were on the lowest-risk products, such as the APIs, which have other controls on them as they go through the drug manufacturing process. The second part of that is that we were building on a lot of work that we'd done internationally with confidence building through our international partner organizations on how best to use that type of information. We would still prioritize for in-person inspection anything that would be of higher risk, again not just because of the product but because of potential issues with any of the other finished products that would go into them.
Really it's a risk-based approach that we take to inspections, and the pandemic allowed us to pilot a few other IT solutions as well that helped enable those inspections.